Coeptis Therapeutics Holdings, Inc. (COEP)
2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-09-30 | |
|---|---|---|---|---|
| Selling and marketing expense | - | 5,000 | - | 12,412 |
| Share based compensation | 96,888 | 611,570 | - | - |
| Salary expense | 378,740 | 459,099 | 445,359 | - |
| Research and development expense | 811,784 | 398,817 | 777,069 | 5,072,938 |
| Professional services expense | 431,304 | 864,588 | 1,180,499 | - |
| General and administrative expenses | 173,073 | 239,028 | 269,456 | 2,815,870 |
| Amortization expense | 250,000 | 250,000 | 250,000 | - |
| Operating expenses | 2,141,789 | 2,828,102 | 2,922,383 | 7,921,020 |
| Operating income (loss) | -2,141,789 | -2,828,102 | -2,922,383 | -7,921,020 |
| Royalty expense | - | - | - | 15,000 |
| Gain on change in fair value of derivative liability warrants | - | - | - | 1,609,125 |
| Interest expense | - | 66,056 | - | 19,800 |
| Change in fair value of derivative liability warrants | - | -149,250 | 34,875 | - |
| Other income (expense) | 51,558 | 8,063 | 86,625 | -23,601 |
| Interest expense, nonoperating | 50,926 | - | 200,505 | - |
| Disposal group, not discontinued operation, loss (gain) on write-down | 37,257 | - | - | - |
| Change in fair value of derivative liability warrants | 349,500 | - | - | - |
| Nonoperating income (expense) | 312,875 | -207,243 | -79,005 | 1,570,524 |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | -1,828,914 | -3,035,345 | -3,001,388 | -6,350,494 |
| Net income (loss), including portion attributable to noncontrolling interest | -1,828,914 | -3,035,345 | - | - |
| Net loss | -1,828,914 | -3,035,345 | -3,001,388 | -6,350,494 |
| Basic eps | -0.05 | -0.08 | -0.08 | -0.24 |
| Diluted eps | -0.05 | -0.08 | -0.08 | -0.24 |
| Basic average shares | 39,806,505 | 37,569,312 | 35,544,709 | 26,650,210 |
| Diluted average shares | 39,806,505 | 37,569,312 | 35,544,709 | 26,650,210 |